Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Our adviser: Drugs Infromation online


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION


         

 

On April 2, San Camillo Hospital in Rome discharged its first patient to be bridged to transplant with SynCardia’s Total Artificial Heart. On Feb. 23, after 832 days of life with the Total Artificial Heart, Giuseppe Nicotera received the heart transplant he’d been waiting for more than two years…

 

For the first time, scientists at Toronto General Hospital, University Health Network have shown in a clinical trial that the Toronto XVIVO System can safely and effectively treat, re-assess and improve the function of high-risk donor lungs so that they can be successfully transplanted into patients…

 

Simple changes to how ventilators are used could almost double the number of lungs available for transplants, according to new international research involving a doctor at St. Michael’s Hospital. Many potential donor lungs deteriorate between the time a patient is declared brain dead and the time the lungs are evaluated to determine whether they are suitable for transplant…

 

Using lab mice genetically bred to express immune cell proteins in different fluorescent colors, US researchers have developed a new imaging system that differentiates protective and destructive T-cells, enabling them to assess the health of transplanted tissue by visualizing immune cell responses in real time…

 

During 2008, 10% of people who were implanted with the SynCardia temporary CardioWest™ Total Artificial Heart received the device because they were suffering from rejection of their donor heart transplant. Jim Hennigan, 44, received his first heart transplant in 2004 but suffered from rejection of the new heart.

 

The U.S. Patent and Trademark Office is reviewing a University of Rhode Island pharmacy professor’s proposal to use saliva as a non-invasive way to monitor concentrations of anti-rejection drugs in patients that undergo transplants. Associate Professor of Pharmacy Fatemeh Akhlaghi said saliva offers a pain-free way to measure levels of immunosuppressive agents such as cyclosporine, and mycophenolic acid, which are essential in preventing organ rejection after transplantation.

 

A 14-year old American girl was kept alive for 118 days without a heart while waiting for a second heart transplant at a hospital in Florida; surgeons fitted a custom-made artificial heart after removing the first transplanted heart in July this year. D’Zhana Simmons, who lives in South Carolina, had her first heart transplant on 2nd July at Holtz Children’s Hospital at the University of Miami/Jackson Memorial Medical Center.

 

The Swedish biotech company AbSorber has been given clearance by the U.S. Food and Drug Administration (FDA) to market and sell its XM-ONE® transplantation test in the U.S. Initially, sales of XM-ONE® in the U.S. will target the kidney transplantation market valued at approximately SEK 200 million. XM-ONE® previously received CE marking and is approved for sales within the EU.

 

Seven years after Joaquin Lucio’s kidneys shut down, he had a heart attack and was taken to a Los Angeles area hospital where doctors performed an angioplasty to clear his coronary arteries. He also was suffering from idiopathic congestive heart failure - a condition in which the heart becomes weak and enlarged - and a special pacemaker was implanted to provide support.




May 2012
Mon Tue Wed Thu Fri Sat Sun
« Apr    
 123456
78910111213
14151617181920
21222324252627
28293031